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Abstract
Transforming growth factor (TGF)-β1 is a pluripotent cytokine that profoundly inhibits
epithelial proliferation, induces apoptosis, and influences morphogenesis by mediating
extracellular matrix deposition and remodeling. The physiologic roles of the action of TGF-β
in mammary gland, indeed in most tissues, are poorly understood. In order to understand the
actions of TGF-β, we need to take into account the complexity of its effects on different cell
types and the influence of context on cellular responses. This task is further compounded by
multiple mechanisms for regulating TGF-β transcription, translation, and activity. One of the
most significant factors that obscures the action of TGF-β is that it is secreted as a stable
latent complex, which consists of the 24-kDa cytokine and the 80-kDa dimer of its prepro
region, called latency-associated peptide. Latency imposes a critical restraint on TGF-β
activity that is often overlooked. The extracellular process known as activation, in which
TGF-β is released from the latent complex, is emphasized in the present discussion of the
role of TGF-β in mammary gland development. Definition of the spatial and temporal patterns
of latent TGF-β activation in situ is essential for understanding the specific roles that TGF-β
plays during mammary gland development, proliferation, and morphogenesis.
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Introduction
This review describes briefly mammary gland develop-
ment and discusses the postulated role of TGF-β1 in
mammary gland development as evidenced by its effects
in mammary epithelial cell culture and animal studies.
TGF-β has been strongly implicated in the control of
mammary epithelial growth [1] and in breast cancer cells
[2,3]. Cell culture studies have also shown that the
effects of TGF-β are pleiotropic, context-dependent, con-
centration-dependent, and can be indirect. As a conse-
quence it is difficult to predict the endogenous action of
TGF-β in mammary gland. However, mammary gland
mouse models in which exogenous TGF-β or blocking
antibodies are administered indicate that regulation of
growth and morphogenesis is a potential function of
TGF-β (Fig. 1). Transgenic models in which the activity of
TGF-β is manipulated have confirmed this conclusion.
Interpretation of these animal studies are confounded by
the fact that the lack of knowledge about when and
where TGF-β is active in situ, however. Preliminary
studies from our laboratory have provided an indication of
the complexity that awaits analysis of in situ activity.
http://breast-cancer-research.com/content/2/2/092
Mammary gland development
The seminal work of Daniel and coworkers [4••,5] focused
attention on the role of TGF-β in mammary gland develop-
ment soon after its characterization. The morphologic and
functional development of the mammary gland is largely
postnatal in both humans and mice (for review [6]). Under
the effects of hormones of puberty, which begins just after
weaning in mice and continues for several weeks (ie 3
weeks to 6–8 weeks of age), the mammary tree is estab-
lished within an adipose stroma known as the fat pad. The
epithelium, usually a simple epithelium consisting of one or
two cell layers, is ensheathed in a fibrous stroma. This
period of growth is characterized by a specialized morpho-
logic unit called the end-bud, which is a multicellular, mul-
tilayered structure whose function is to extend the ductal
epithelial tree to the boundaries of the fat pad. The pattern
of the resulting tissue can be visualized in a whole-mount
preparation and is often used as an end-point for evaluat-
ing the role of factors such as TGF-β in guiding morphol-
ogy by measuring the extent of branching, the branching
pattern by branch-point analysis, and the distribution of
end-buds and their character, size, shape, and persis-
tence. Once the ductal tree is established, repeated
estrus cycles of ovarian hormones elicit further elaboration
of the epithelium in some mouse strains, generating small
lateral branch points. In a nulliparous animal approximately
10% of the tissue is epithelial.
Under the effects of hormones of pregnancy, a burst of
growth and differentiation results in lobuloalveolar differen-
tiation of the epithelium into functional secretory units that
produce milk that is carried to the teat by large conducting
ducts. The resulting fully functional gland is 90% epithelial.
Upon weaning, a process of involution destroys the major-
ity of secretory epithelium, leaving the ductal tree extant
for repeated cycles of growth and differentiation.
The remarkable capacity of the mammary epithelium to
undergo development and differentiation provides a
research model in which the factors that influence growth,
morphologic patterning, proliferation, and differentiation
can readily be explored. Furthermore, in mice epithelium
can be transplanted to new stroma that is usually cleared
of endogenous epithelium, which offers an exceptional
research tool for studying the contribution of the stroma to
the control of epithelial function and remodeling. Recombi-
nations of transgenic and wild-type epithelia and stromas,
and the ability to transplant intact fat pads to new hosts,
allows determination of whether the source of a particular
factor (ie different tissue compartments) affects the matu-
ration of the mammary gland.
Transforming growth factor-β regulation and
expression
There are three mammalian isoforms of TGF-β. All three
isoforms bind to the same cell surface receptors and, in
cell culture, often appear to elicit similar responses. For
the purposes of this review we focus on the well-studied
TGF-β1 isoform, its localization in the mammary gland, its
effects in cell culture models, and the consequences of
manipulating its activity in vivo by various means. The
activity of all TGF-β isoforms is restrained by secretion as
latent complexes [latent transforming growth factor
(LTGF)-β] [7]. (Regarding nomenclature, TGF-β refers to
the active cytokine or its effects, whereas LTGF-β desig-
nates the latent form.) LTGF-β consists of the 24-kDa
cytokine and a 80-kDa dimer of its prepro region called
latency-associated peptide (LAP), which contains the
signal sequence for secretion (Fig. 2). To our knowledge,
all cells secrete LTGF-β, which underscores the impor-
tance of activation events associated with the release of
TGF-β from LAP.
TGF-β message levels do not usually reflect protein pro-
duction, or, more importantly, protein activity. For example,
tamoxifen increases both LTGF-β production and activa-
tion without any effect on mRNA levels [2]. Differences in
mRNA translation are in part due to a 5′-untranslated
region stem-loop that binds a regulatory protein, which
can result in increased protein production by factors of 10
without changes in mRNA levels [8]. In addition, protein
assays are complicated by the fact that tissue extraction
protocols activate the endogenous LTGF-β [9]. Because
the biologic activity of TGF-β is controlled by its release
from the latent complex, elevated expression of latent
complex is not likely to have biologic consequences,
whereas increased activation, even without changes in
synthesis, will profoundly affect physiologic events [10].
The importance of activation is supported by the lack of a
phenotype in transgenic mice that overexpress LTGF-β in
mammary gland [11•]. A recent study in TGF-β-null het-
erozygotes, however, has shown there is a dramatic loss
of circulating and tissue TGF-β levels as a result of the
Figure 1
Effects of transforming growth factor (TGF)-β in mammary gland. A
variety of studies suggest that TGF-β contributes to morphogenesis,
growth, and function in mouse mammary gland.
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haploid genotype [12•]. This surprising finding indicates
that TGF-β plays a significant role in its own regulation.
A variety of immunostaining studies have been conducted
in both murine and human tissues. These are difficult to
summarize because of differences in tissue preparation,
the antibodies employed, and their uncertain relevance to
understanding the functional role of TGF-β in situ.
Several studies localized TGF-β to the human breast
epithelium and stroma [13,14], but at least one study [15]
found it to be associated only with epithelial cells; this is
probably due to either the antibody or fixative (see
below). TGF-β is also found in the conditioned media of
cultured normal human epithelial cells [16–18] and
fibroblasts [18,19]. A recent study that immunolocalized
TGF-β receptors I, II, and III in normal human breast [20]
demonstrated that these are widely expressed in the
breast epithelium and stroma.
Robinson et al [21•] used Northern blot analyses, in situ
hybridization, and immunocytochemistry to define TGF-β
expression patterns during murine mammary gland devel-
opment and differentiation to establish that all three mam-
malian TGF-β isoforms are expressed in the epithelium
during all phases of mammary development. TGF-β2 was
less abundant, however, whereas TGF-β3 was the only
isoform found in myoepithelial cells. TGF-β1 transcripts
and immunoreactivity decreased during pregnancy, but
those of TGF-β2 and TGF-β3 increased until the onset of
lactation [210•]. Intraepithelial immunoreactivity in that
study corresponded to transcript localization, indicating
sites of synthesis. Immunolocalization using antibodies to
mature TGF-β versus TGF-β1 LAP showed an interesting
pattern of deposition that was suggested to indicate that
TGF-β activity inhibits proliferation and its depletion is
necessary for growth [22]. Although activation was
implicit in the interpretation of the immunostaining, the
model did not provide confirmation of activity, due in large
part to the lack of reagents to differentially localize active
TGF-β versus LTGF-β.
Studies in our laboratory demonstrate that under certain
conditions some antibodies can discriminate between
active and latent TGF-β [23]. We determined the speci-
ficity of TGF-β antibodies by using a immunodetection
method that preserves endogenous LTGF-β in conjunction
with engineered control tissues that specifically produce
latent versus constituitively active TGF-β [24••]. Our exten-
sive screening of available TGF-β antibodies demon-
strated that antibody source, fixation, and tissue
preparation influences the ability to discriminate between
active and latent forms [25•]; thus, retrospective interpre-
tation of other immunostaining protocols and antibodies
combinations is not possible.
One of the most striking features of our immunolocaliza-
tion in mammary gland using antibodies that discriminate
between TGF-β and LTGF-β is the contrast between the
highly restricted localization of TGF-β compared with the
broad distribution of LTGF-β. Our initial studies concerned
the effect of ionizing radiation on the mammary gland
microenvironment. We observed that the immunoreactivity
of activation-specific antibodies LC(1-30) and CC(1-30)
is restricted to the normal mammary epithelium [26],
whereas LAP immunoreactivity is widely distributed in the
epithelium, fibrous stroma, and adipose stroma [24••]. A
remarkably rapid (within 1 h) shift from predominantly LAP
to TGF-β immunoreactivity in all of these tissue compart-
ments led us to conclude that ionizing radiation leads to
LTGF-β activation [24••]. Our conclusion is supported by
additional studies that demonstrated that radiation
induces stromal extracellular matrix (ECM) remodeling (eg
collagen III), a known target of TGF-β action [26], and that
administration of TGF-β-neutralizing antibodies blocks
ECM remodeling in irradiated animals [27]. These studies
indicated that, despite the apparent abundance of LTGF-β
in normal, nulliparous mammary gland, active TGF-β is
highly localized.
Figure 2
Transforming growth factor (TGF)-β production, secretion, and
activation. Some elements of protein processing and post-translation
modifications involved in the regulatory control of TGF-β are depicted.
The TGF-β1 gene encodes a 390 amino acid polypeptide that is
cleaved into two polypeptides that form homodimers during protein
processing: latency-associated peptide (LAP) and TGF-β. These
homodimers are noncovalently associated to form the small latent
TGF-β complex, which is secreted. Alternatively, this complex can be
covalently linked by disulfide bonds to a latent TGF-β binding protein
(LTBP) before secretion. LTBP provides means of anchoring latent
TGF (LTGF)-β in the extracellular matrix (ECM), which may involve
cross-linking by transglutaminase and which requires proteolytic
processing to release LTGF-β before activation. Activation occurs
extracellularly to release TGF-β at or near the cell surface so that it
immediately binds to its receptors. TGF-β receptors I and II form a
heterocomplex that signals via the SMAD signal transduction protein
family. TGF-β receptor III, also known as betaglycan, is nonsignaling
but may be involved in presenting TGF-β to its signaling receptors.
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Transforming growth factor-β responses in
cultured cell models
Much of our understanding of the biology of TGF-β comes
from studies of cultured cells exposed to recombinant or
purified active TGF-β. Nonetheless, the specific physio-
logic roles of the action of TGF-β in mammary gland are
not well understood, which is due in part to the complexity
of its effects on different cell types that is compounded by
regulation at multiple levels and modified by cellular
context [23]. Examples of these effects are summarized
below. TGF-β has been shown to inhibit profoundly prolif-
eration of normal rodent and human mammary epithelial
cells in cell culture, and may also modify the production of
differentiated proteins (for review [28]). Both cell type and
context influence TGF-β action. 3T3 cell preadipocytes
spontaneously activate their own secreted LTGF-β,
whereas mature adipocytes do not, which implicates
TGF-β activation as a potent negative regulator of
adipocyte differentiation [29]. Fetal versus adult fibro-
blasts [30], young versus old smooth muscle cells [31],
and normal human mammary epithelial cells grown on
ECM versus plastic [32] are differentially sensitive to
TGF-β growth inhibition. In addition to reversible growth
inhibition, TGF-β can also induce apoptosis. Hormone
withdrawal in hormone-dependent tissues such as
prostate [33•] and uterus [34•] is a potent inducer of
TGF-β-mediated apoptosis. In mammary gland, TGF-β
mRNA increases early in involution and its activity is
thought to mediate this apoptotic remodeling process
[35]. Notably, mammary secretions during involution
contain high levels of active TGF-β and extremely high
levels of LTGF-β that regulate the mononuclear phago-
cytes involved in apoptotic remodeling of the gland [36].
TGF-β-induced ECM contributes to growth control in cul-
tured cells [37] and may be involved in the changes in
ECM during mammary gland development [13,22] and the
menstrual cycle [38]. The cessation of DNA synthesis and
end-bud regression caused by exogenous TGF-β-induced
ECM is postulated to involve the concomitant induction of
periepithelial ECM around end-buds [39]. This regulation
may be offset by feedback mechanisms as evidenced by
suppression of TGF-β-induced ECM mRNA levels in
murine mammary cells cultured within a basement mem-
brane-type ECM [40]. Even cells that lack a proliferative
response to TGF-β-induced ECM, such as breast cancer
cells, may still respond with specialized ECM production
[16], that in turn may modify the tissue microenvironment
in such a way as to affect growth. For example, recent
mammary cell culture studies [41] also point to a role of
ECM in modulating hormone response. The antiestrogen
tamoxifen affects stromal production and activity of TGF-β,
which has been postulated to contribute to its therapeutic
benefit [42]. An interesting model of hormone-mediated
remodeling in uterine tissue indicates that stromal activa-
tion of TGF-β mediates epithelial production of the pro-
teases that are necessary for degradation of basement
membrane [43•].
The addition of TGF-β to mammary cell cultures supports
a role in regulation of morphogenesis and control of differ-
entiation. TGF-β suppressed the ability of mammary
explants cultured with lactogenic hormones to secrete
casein [44]. It abolished ductal morphogenesis by human
mammary epithelial cells cultured within a basement mem-
brane-type ECM, whereas antibodies to TGF-β stimulated
duct formation [45]. In another study [46], however, cul-
tured mammary cell lines exhibited a biphasic response to
TGF-β concentration; picomolar concentrations inhibited
branching morphogenesis, whereas fentomolar concentra-
tions stimulated it. Furthermore, chronic TGF-β exposure
can elicit phenotypic transformation under certain condi-
tions, resulting in the acquisition of mesenchymal-like
transformation of mammary epithelial cells [47], or myofi-
broblast characteristics in stromal cells [48]. The role of
such phenomena in vivo remains obscure, but may con-
tribute to desmoplasia and invasive behavior in neoplasia.
Manipulating transforming growth factor-β
activity in the mammary gland
The consequences of endogenous TGF-β activity in the
mammary gland have been evaluated by using exogenous
delivery of TGF-β or neutralizing antibodies. The pivotal
observations by Daniel and coworkers [4••,5], who admin-
istered exogenous TGF-β via diffusion from miniature inor-
ganic pellets, showed that end-buds undergo reversible
regression during puberty, whereas alveolar buds in preg-
nancy, which are also actively proliferating, do not. During
puberty, end-bud DNA synthesis was profoundly inhibited
within 12 h of exposure to TGF-β-containing implants, and
by 48 h this resulted in an 80–90% decrease in end-bud
number [4••]. In contrast, DNA synthesis in distal ductal
epithelium and fibroblasts was unaffected, indicating an
underlying difference in responses and/or access to these
cells. End-bud regression was preceded by the deposition
of a thick, collagen- and glycosoaminoglycan-rich ECM,
which was postulated to force premature differentiation
[49]. This selective regression of end-buds was reversible
if the implant was removed, even after long-term expo-
sures [5], indicating that the gland did not become refrac-
tory or lose its multipotent stem-cell population. In
contrast, exogenous TGF-β did not inhibit lobuloalveolar
growth, morphogenesis or differentiation. This stage
specificity belies a simple role for TGF-β as a DNA synthe-
sis inhibitor and points to the possible differences in how
these two actively proliferating structures are regulated. It
may also indicate that endogenous TGF-β activity is differ-
entially regulated during these distinct phases of concomi-
tant mammary gland growth and differentiation.
Transgenic manipulation of TGF-β in mammary gland
underscores the importance of defining when and where
the protein is active. As mentioned above, overexpression
of LTGF-β does not produce a mammary phenotype.
TGF-β can be produced in a constitutively active form by
expression of a construct in which the cysteines at posi-
tions 223 and 225 are mutated to serines, however, pre-
venting dimerization of LAP [50]. Two transgenic models
have been created with dramatically different phenotypes,
depending on the promoter that is used to drive expres-
sion of the transgene. Murine mammary tumor virus
(MMTV)-long terminal repeat promoter is used to direct
transgene expression to the mammary epithelium. When
TGF-β223-225 is expressed on an MMTV promoter, the gland
is transiently hypoplastic during ductal morphogenesis, but
recovers and is able to lactate and support offspring without
apparent difficulty [11•]. It has been suggested by Smith
[51] that additional expression of the MMTV-driven trans-
gene in the salivary gland may influence this phenotype. If
the mutated constitutively active TGF-β is driven by the
whey acidic protein (WAP) promoter, however, a milk
protein that is highly expressed during pregnancy and lacta-
tion, ductal morphogenesis is unaffected, but alveolar devel-
opment is greatly compromised [52••].
Subsequent experiments demonstrated that proliferation
was uninhibited but that apoptosis was stimulated during
both estrous and pregnancy [53••]. Furthermore, trans-
plant experiments indicated that the action of TGF-β was
intrinsic to the epithelial cells and acted in an autocrine
manner. For example, wild-type epithelium was unaffected
and differentiated normally [53••]. Taking full advantage of
the mammary model, Kordon et al [53••] used serial trans-
plantation of WAP-TGF-β223-225 epithelium to show that
the mammary stem cells were significantly compromised
by the transgene expression. Because endogenous WAP
protein or reporter expression is restricted to specific
luminal epithelial cells and is regulated by the estrus cycle,
those investigators postulated that WAP-TGF-β223-225
expression targeted the immediate daughters of mammary
epithelial cells, causing inappropriate apoptosis and sub-
sequent depletion of this compartment. The severity of the
MMTV-TGF-β223-225 phenotype may also be influenced by
the timing or cell specificity of expression relative to that of
endogenous LTGF-β activation. Our preliminary data using
antibodies that discriminate between active and latent
TGF-β supports this concept in that TGF-β activation is
suppressed by mid to late pregnancy. Thus, WAP-
TGF-β223-225 would be driving inappropriate TGF-β activity
at a point when it is normally inhibited.
The question of how mammary glands of TGF-β-null mice
develop has not yet been addressed because the null
mice die around the time of mammary gland development
[54]. These mice have provided evidence of a previously
unrecognized aspect of TGF-β biology, however. Letterio
et al [55] demonstrated that homozygous TGF-β-null off-
spring are protected from the gross inflammation that
leads to their early death by maternal transfer of TGF-β via
the placenta and milk. Another surprising aspect of the
TGF-β1-null mouse is that the haploid genotype leads to
greatly reduced TGF-β production, which is reflected by
serum levels that are 11% of the levels in wild-type
animals, indicating that TGF-β regulates its own produc-
tion and/or stability. This chronic depletion of the latent
complex pools presumably restricts TGF-β activity, and
results in a subtly altered proliferative phenotype in liver
and lung. A further consequence is increased tumor devel-
opment, indicating that TGF-β is sufficiently depleted to
impede its action as a tumor suppressor [12•].
We recently evaluated the mammary gland phenotype of
TGF-β-null heterozygote mutant mice (Barcellos-Hoff MH,
et al, unpublished data). Mammary ductal outgrowth
during puberty was accelerated, and mammary epithelial
proliferation was increased in young TGF-β1 haploid geno-
type animals. This effect appeared to be stage-specific in
that mammary gland whole mounts from adult nulliparous
mice were grossly normal in morphology and functionally
intact. Despite the apparently normal morphology, we
found that the frequency of proliferating cells of the
mammary epithelium is significantly elevated in mammary
gland, as occurs in other tissues like liver from TGF-β-null
mutant heterozygotes [12•].
It is unknown at this time whether systemic, stromal,
epithelial or all sources of TGF-β are critical in defining the
rate of growth in mammary gland. Gorska et al [56]
addressed this question by overexpressing a dominant-
negative kinase-deficient TGF-β type II receptor driven by
MMTV-long terminal repeat, resulting in primarily epithelial
expression, or metallothionein-derived promoter, which is
expressed in the stroma. The dominant-negative receptor
impedes signaling by all TGF-β isoforms, but circumvents
the issues raised by constitutively active TGF-β trans-
genes. Blunting the response to TGF-β in the mammary
epithelium resulted in alveolar hyperplasia and premature
functional differentiation. In contrast, inhibition of the
stromal response to TGF-β by this means resulted in
increased ductal branching [57]. Thus, both stromal and
epithelial responses to TGF-β activity play a role in defin-
ing the maturation of mammary tissue.
The question of when and where LTGF-β is activated
during normal development and homeostasis remains to
be addressed, however. We recently developed dual
immunofluorescence of LAP antibodies and activation-
specific chNTGF-β antibodies [27] and have begun to
study the pattern of localization during mouse mammary
gland development and differentiation (Fig. 3). Although
LAP immunoreactivity (green) is relatively uniform, a het-
erogeneous pattern of TGF-β staining (yellow-orange) is
observed in the epithelium of adult mammary glands (Bar-
cellos-Hoff MH et al, unpublished data). We have exam-
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ined mammary glands from a variety of developmental
states to determine the physiologic correlates of this
pattern. We found that mammary epithelial TGF-β
immunoreactivity was heterogeneous and most intense
during periods of proliferation and morphogenesis, sug-
gesting the presence of a distinct subpopulation. Further
characterization of these cells and determination of their
ultimate fate in terms of proliferation and differentiation
may be informative regarding the cellular mechanisms by
which pattern and function are established during
mammary gland development.
Conclusion
It is clear from a variety of studies in cell culture that
TGF-β can have myriad effects, many of which comple-
ment each other, but others that appear paradoxic. In vivo
studies using exposure to exogenous sources or trans-
genic expression of constitutively active protein have
shown what TGF-β can do in the mammary gland. These
have generally led to the conclusion that TGF-β has a
prominent role in regulating pattern formation by the
epithelium, perhaps via interactions with the stroma, and is
involved in fate decisions by individual cells. In the great
majority of animal and cell culture studies, however, activa-
tion of the ubiquitous latent TGF-β complex, which exer-
cises fundamental control of TGF-β action, has been
scarcely addressed, which is due in large part to the lack
of appropriate tools and reagents. As evidenced by the
WAP-TGF-β223-225 versus the MMTV-TGF-β223-225 trans-
genic phenotypes, spatial and temporal patterns of LTGF-β
activation are key elements for to understanding the spe-
cific consequences of TGF-β activity during mammary
gland development. Likewise, similar studies of the relative
activity of the different TGF-β isoforms in the mammary
gland may help shed light on the need for this apparent
redundancy. Finally, studies that address mechanisms of
activation may then contribute to strategies for manipula-
tion of TGF-β in situ and lead to a better understanding of
how its dysregulation contributes to carcinogenesis [58].
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